XTL Biopharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell XTLB and other ETFs, options, and stocks.

About XTLB

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its product pipeline includes hCDR1 and rHuEPO. 

CEO
Noam Band
CEONoam Band
Employees
11
Employees11
Headquarters
Ramat Gan, Tel Aviv
HeadquartersRamat Gan, Tel Aviv
Founded
1993
Founded1993
Employees
11
Employees11

XTLB Key Statistics

Market cap
7.67M
Market cap7.67M
Price-Earnings ratio
-7.25
Price-Earnings ratio-7.25
Dividend yield
Dividend yield
Average volume
25.18K
Average volume25.18K
High today
$0.824
High today$0.824
Low today
$0.717
Low today$0.717
Open price
$0.717
Open price$0.717
Volume
24.26K
Volume24.26K
52 Week high
$2.57
52 Week high$2.57
52 Week low
$0.5301
52 Week low$0.5301

XTLB News

TipRanks 5d
XTL Biopharmaceuticals Faces Nasdaq Delisting After “Public Shell” Determination

An update from XTL Biopharmaceuticals Sponsored ADR ( (XTLB) ) is now available. On February 27, 2026, XTL Biopharmaceuticals disclosed that Nasdaq’s Listing Q...

TipRanks 5d
XTL Biopharmaceuticals gets delisting letter from Nasdaq, to request hearing

XTL Biopharmaceuticals (XTLB) announced that it has received a letter from Nasdaq, dated February 25, notifying the company of the staff’s belief, based upon it...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.